Literature DB >> 7726528

Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides.

J C Fung-Tomc1, E Huczko, T Stickle, B Minassian, B Kolek, K Denbleyker, D Bonner, R Kessler.   

Abstract

Thirteen oral cephems (cefprozil, loracarbef, cefaclor, cefuroxime axetil, cefpodoxime proxetil, cefetamet pivoxil, cefixime, cefdinir, cefadroxil, cephradine, cephalexin, cefatrizine, and cefroxadine), the cephalosporin class representative cephalothin, cefazolin, and the macrolides erythromycin, clarithromycin, and azithromycin were compared for their antibacterial activities against 790 recent clinical isolates. These oral agents differed in their spectra and antibacterial potencies against community-acquired pathogens.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7726528      PMCID： PMC162574          DOI： 10.1128/AAC.39.2.533

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970-1990.

Authors:  P Geslin; A Buu-Hoi; A Frémaux; J F Acar
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 3.  Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria.

Authors:  R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

4.  Inability of cephalothin testing to predict cefprozil susceptibility.

Authors:  J Fung-Tomc; T Stickle; C Doyle; E Huczko; R E Kessler
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

5.  Evolution and epidemiology of MLS resistance.

Authors:  J Duval
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

6.  Reliability of cefaclor, cefazolin, cefamandole, and cephalothin disks to predict susceptibility of Enterobacteriaceae, Staphylococcus species, and Haemophilus influenzae.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Am J Clin Pathol       Date:  1985-11       Impact factor: 2.493

7.  High rates of erythromycin-resistant Streptococcus pneumoniae among penicillin-resistant strains.

Authors:  F Soriano; R Fernández-Roblas
Journal:  J Antimicrob Chemother       Date:  1993-03       Impact factor: 5.790

8.  Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland.

Authors:  H Seppälä; A Nissinen; Q Yu; P Huovinen
Journal:  J Antimicrob Chemother       Date:  1993-12       Impact factor: 5.790

9.  Variable in vitro activity of cefaclor, cephalothin and cefadroxil against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.

Authors:  P Larsson; K Lincoln; L Lind; T Sandberg
Journal:  Scand J Infect Dis       Date:  1988

10.  Reassessment of the "class" concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporins.

Authors:  A L Barry; C Thornsberry; R N Jones; P C Fuchs; T L Gavan; E H Gerlach
Journal:  Am J Clin Pathol       Date:  1978-12       Impact factor: 2.493
  10 in total
  9 in total

1.  Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.

Authors:  M W Garrison; C L Malone; J E Eiland
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Optimal management of uncomplicated skin and skin structure infections of the lower extremity.

Authors:  Warren S Joseph
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

3.  Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group.

Authors:  J M Gwaltney; S Savolainen; P Rivas; P Schenk; W M Scheld; A Sydnor; C Keyserling; A Leigh; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group.

Authors:  K J Tack; C H Keyserling; J McCarty; J A Hedrick
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 5.  Cefprozil: a review.

Authors:  Sumit Bhargava; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2003-05       Impact factor: 1.967

6.  Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997.

Authors:  P A Hogan; D J Sheehan
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 7.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

8.  Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans.

Authors:  Ji-Hun Jang; Seung-Hyun Jeong; Hea-Young Cho; Yong-Bok Lee
Journal:  Pharmaceutics       Date:  2019-10-14       Impact factor: 6.321

9.  Cefadroxil Comparable to Cephalexin: Minimum Inhibitory Concentrations among Methicillin-Susceptible Staphylococcus aureus Isolates from Pediatric Musculoskeletal Infections.

Authors:  Andrew S Haynes; Andrea Prinzi; Lori J Silveira; Sarah K Parker; Jed N Lampe; Jeffrey S Kavanaugh; Alexander R Horswill; Douglas Fish
Journal:  Microbiol Spectr       Date:  2022-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.